Curis Lifescien.
: CURIS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Curis Lifescien.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Curis Lifesciences Limited is a pharmaceutical company established in 2010 that specialises in the development, manufacturing, and distribution of diverse medicinal formulations. Its product portfolio encompasses tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.
Business Model
The company generates revenue through the manufacturing and distribution of a broad range of pharmaceutical formulations across multiple dosage forms.
Growth Outlook
Growth is expected to be driven by the expansion of its diverse product manufacturing capabilities and the distribution of its pharmaceutical formulations.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. The pharmaceutical sector is highly competitive, which may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients could impact production efficiency.
- Product Liability. As a manufacturer of medicinal products, the company is exposed to potential legal and reputational risks associated with product quality or safety issues.
Start your research today
Unlock AI insights, financials, peers and live data on Curis Lifescien. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Curis Lifescien.CURIS | ₹103 Cr | — | — | — | 18.4% | — | — | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Curis Lifescien.
: CURIS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Curis Lifescien.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Curis Lifesciences Limited is a pharmaceutical company established in 2010 that specialises in the development, manufacturing, and distribution of diverse medicinal formulations. Its product portfolio encompasses tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.
Business Model
The company generates revenue through the manufacturing and distribution of a broad range of pharmaceutical formulations across multiple dosage forms.
Growth Outlook
Growth is expected to be driven by the expansion of its diverse product manufacturing capabilities and the distribution of its pharmaceutical formulations.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. The pharmaceutical sector is highly competitive, which may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients could impact production efficiency.
- Product Liability. As a manufacturer of medicinal products, the company is exposed to potential legal and reputational risks associated with product quality or safety issues.
Start your research today
Unlock AI insights, financials, peers and live data on Curis Lifescien. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026